10-Q 1 rop-20220331.htm 10-Q rop-20220331
000088283512/312022Q1false00008828352022-01-012022-03-3100008828352022-04-29xbrli:sharesiso4217:USD00008828352021-01-012021-03-31iso4217:USDxbrli:shares00008828352022-03-3100008828352021-12-3100008828352020-12-3100008828352021-03-310000882835us-gaap:CommonStockMember2021-12-310000882835us-gaap:AdditionalPaidInCapitalMember2021-12-310000882835us-gaap:RetainedEarningsMember2021-12-310000882835us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000882835us-gaap:TreasuryStockMember2021-12-310000882835us-gaap:RetainedEarningsMember2022-01-012022-03-310000882835us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000882835us-gaap:TreasuryStockMember2022-01-012022-03-310000882835us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000882835us-gaap:CommonStockMember2022-03-310000882835us-gaap:AdditionalPaidInCapitalMember2022-03-310000882835us-gaap:RetainedEarningsMember2022-03-310000882835us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000882835us-gaap:TreasuryStockMember2022-03-310000882835us-gaap:CommonStockMember2020-12-310000882835us-gaap:AdditionalPaidInCapitalMember2020-12-310000882835us-gaap:RetainedEarningsMember2020-12-310000882835us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000882835us-gaap:TreasuryStockMember2020-12-310000882835us-gaap:RetainedEarningsMember2021-01-012021-03-310000882835us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000882835us-gaap:TreasuryStockMember2021-01-012021-03-310000882835us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000882835us-gaap:CommonStockMember2021-03-310000882835us-gaap:AdditionalPaidInCapitalMember2021-03-310000882835us-gaap:RetainedEarningsMember2021-03-310000882835us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000882835us-gaap:TreasuryStockMember2021-03-31rop:divestiture0000882835us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-03-310000882835us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-03-310000882835us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2022-03-310000882835us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CustomerRelationshipsMember2022-01-012022-03-310000882835us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-03-310000882835us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:TechnologyBasedIntangibleAssetsMember2022-01-012022-03-310000882835rop:SedaruIncMember2021-03-172021-03-170000882835rop:SingaporeTechnologiesEngineeringLtdAffiliateMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMemberrop:TransCoreMember2022-03-170000882835rop:SingaporeTechnologiesEngineeringLtdAffiliateMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMemberrop:TransCoreMember2022-03-172022-03-170000882835us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberrop:EddyfiNDTIncMemberrop:ZetecMember2022-01-050000882835us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberrop:EddyfiNDTIncMemberrop:ZetecMember2022-01-052022-01-050000882835us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberrop:TransCoreHoldingsIncZetecAndCivcoRadiotherapyMember2021-12-310000882835us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberrop:TransCoreHoldingsIncZetecAndCivcoRadiotherapyMember2022-01-012022-03-310000882835us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberrop:TransCoreHoldingsIncZetecAndCivcoRadiotherapyMember2021-01-012021-03-310000882835us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMemberrop:CivcoRadiotherapyMember2022-01-012022-03-310000882835us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000882835us-gaap:EmployeeStockOptionMember2021-01-012021-03-31xbrli:pure0000882835us-gaap:RestrictedStockMember2022-01-012022-03-310000882835us-gaap:RestrictedStockMember2021-01-012021-03-310000882835us-gaap:EmployeeStockMember2020-07-010000882835us-gaap:EmployeeStockMember2020-07-012020-07-010000882835us-gaap:EmployeeStockMember2022-01-012022-03-310000882835us-gaap:EmployeeStockMember2021-01-012021-03-310000882835rop:ApplicationSoftwareSegmentMember2021-12-310000882835rop:NetworkSoftwareAndSystemsSegmentMember2021-12-310000882835rop:MeasurementAndAnalyticalSolutionsSegmentMember2021-12-310000882835rop:ProcessTechnologiesSegmentMember2021-12-310000882835rop:ApplicationSoftwareSegmentMember2022-01-012022-03-310000882835rop:NetworkSoftwareAndSystemsSegmentMember2022-01-012022-03-310000882835rop:MeasurementAndAnalyticalSolutionsSegmentMember2022-01-012022-03-310000882835rop:ProcessTechnologiesSegmentMember2022-01-012022-03-310000882835rop:ApplicationSoftwareSegmentMember2022-03-310000882835rop:NetworkSoftwareAndSystemsSegmentMember2022-03-310000882835rop:MeasurementAndAnalyticalSolutionsSegmentMember2022-03-310000882835rop:ProcessTechnologiesSegmentMember2022-03-310000882835us-gaap:CustomerRelationshipsMember2021-12-310000882835us-gaap:UnpatentedTechnologyMember2021-12-310000882835us-gaap:ComputerSoftwareIntangibleAssetMember2021-12-310000882835us-gaap:PatentsMember2021-12-310000882835us-gaap:TradeNamesMember2021-12-310000882835us-gaap:TradeNamesMember2021-12-310000882835us-gaap:CustomerRelationshipsMember2022-03-310000882835us-gaap:UnpatentedTechnologyMember2022-03-310000882835us-gaap:ComputerSoftwareIntangibleAssetMember2022-03-310000882835us-gaap:PatentsMember2022-03-310000882835us-gaap:TradeNamesMember2022-03-310000882835us-gaap:TradeNamesMember2022-03-310000882835us-gaap:OtherIntangibleAssetsMember2022-01-012022-03-310000882835us-gaap:OtherIntangibleAssetsMember2021-01-012021-03-310000882835us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDue2022Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:FairValueInputsLevel2Memberrop:SeniorNotesDue2022Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorUnsecuredNotesDueAugust152022Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorUnsecuredNotesDueAugust152022Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDue2023Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDue2023Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDuein2024Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:FairValueInputsLevel2Memberrop:SeniorNotesDuein2024Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDue2025Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDue2025Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorUnsecuredNotesDueSeptember152025Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:FairValueInputsLevel2Memberrop:SeniorUnsecuredNotesDueSeptember152025Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:SeniorNotesMemberrop:SeniorNotesDue2026Member2022-03-310000882835us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberrop:SeniorNotesDue2026Member2022-03-310000882835rop:SeniorUnsecuredNotesDueSeptember152027Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:FairValueInputsLevel2Memberrop:SeniorUnsecuredNotesDueSeptember152027Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:FairValueInputsLevel2Memberrop:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:SeniorNotesMemberrop:SeniorNotesDuein2029Member2022-03-310000882835us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberrop:SeniorNotesDuein2029Member2022-03-310000882835rop:SeniorNotesDueJune2030Memberus-gaap:SeniorNotesMember2022-03-310000882835rop:SeniorNotesDueJune2030Memberus-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2022-03-310000882835us-gaap:SeniorNotesMemberrop:SeniorUnsecuredNotesDueFebruary152031Member2022-03-310000882835us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberrop:SeniorUnsecuredNotesDueFebruary152031Member2022-03-310000882835rop:VertaforeLitigationMember2022-03-31rop:claim0000882835rop:AllenEtAlVVertaforeIncMember2022-03-310000882835rop:MulveyEtAlVVertaforeIncMember2022-03-310000882835rop:VertaforeLitigationMember2022-01-012022-03-31rop:individual0000882835rop:VerathonIncMember2022-01-012022-03-310000882835rop:ApplicationSoftwareSegmentMember2021-01-012021-03-310000882835rop:NetworkSoftwareAndSystemsSegmentMember2021-01-012021-03-310000882835rop:MeasurementAndAnalyticalSolutionsSegmentMember2021-01-012021-03-310000882835rop:ProcessTechnologiesSegmentMember2021-01-012021-03-310000882835rop:ApplicationSoftwareSegmentMember2021-03-310000882835rop:NetworkSoftwareAndSystemsSegmentMember2021-03-310000882835rop:MeasurementAndAnalyticalSolutionsSegmentMember2021-03-310000882835rop:ProcessTechnologiesSegmentMember2021-03-310000882835us-gaap:CorporateNonSegmentMember2022-01-012022-03-310000882835us-gaap:CorporateNonSegmentMember2021-01-012021-03-310000882835rop:SoftwareAndRelatedServicesMember2022-01-012022-03-310000882835rop:SoftwareAndRelatedServicesMember2021-01-012021-03-310000882835rop:EngineeredProductsAndRelatedServicesMember2022-01-012022-03-310000882835rop:EngineeredProductsAndRelatedServicesMember2021-01-012021-03-3100008828352022-04-012022-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022.
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                   to                 .

Commission File Number   1-12273
ROPER TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware51-0263969
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
6901 Professional Parkway, Suite 200
Sarasota,Florida34240
(Address of principal executive offices)(Zip Code)
(941) 556-2601
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
Title of Each ClassTrading Symbol(s)Name of Each Exchange On Which Registered
Common Stock, $0.01 Par ValueROPNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes    No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 Yes    No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes  No
The number of shares outstanding of the registrant’s common stock as of April 29, 2022 was 105,912,655.
1


ROPER TECHNOLOGIES, INC.

REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022

TABLE OF CONTENTS

2


PART I.    FINANCIAL INFORMATION
 
ITEM 1.    FINANCIAL STATEMENTS
 
Roper Technologies, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (unaudited)
(in millions, except per share data)
 
Three months ended March 31,
20222021
Net revenues$1,526.6 $1,376.1 
Cost of sales496.5 440.1 
Gross profit1,030.1 936.0 
Selling, general and administrative expenses609.0 561.4 
Income from operations421.1 374.6 
Interest expense, net52.6 60.6 
Other income (expense), net(1.9)27.1 
Earnings before income taxes366.6 341.1 
Income taxes79.0 71.2 
Net earnings from continuing operations287.6 269.9 
Earnings from discontinued operations, net of tax15.6 19.1 
Gain on disposition of discontinued operations, net of tax1,717.3  
Net earnings from discontinued operations1,732.9 19.1 
Net earnings$2,020.5 $289.0 
Net earnings per share from continuing operations:
Basic$2.72 $2.57 
Diluted$2.70 $2.55 
Net earnings per share from discontinued operations:
Basic$16.41 $0.18 
Diluted$16.24 $0.18 
Net earnings per share:
Basic$19.13 $2.75 
Diluted$18.94 $2.73 
Weighted average common shares outstanding:
Basic105.6 105.0 
Diluted106.7 106.0 

See accompanying notes to Condensed Consolidated Financial Statements.
3


Roper Technologies, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (unaudited)
(in millions)

Three months ended March 31,
20222021
Net earnings$2,020.5 $289.0 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments(22.9)14.6 
Total other comprehensive income (loss), net of tax(22.9)14.6 
Comprehensive income$1,997.6 $303.6 
 
See accompanying notes to Condensed Consolidated Financial Statements.
4


Roper Technologies, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (unaudited)
(in millions)
 
March 31,
2022
December 31,
2021
ASSETS:
Cash and cash equivalents$3,237.5 $351.5 
Accounts receivable, net755.3 839.4 
Inventories, net202.7 176.1 
Income taxes receivable19.2 27.7 
Unbilled receivables110.0 95.3 
Other current assets160.9 142.5 
Current assets held for sale 788.6 
Total current assets4,485.6 2,421.1 
Property, plant and equipment, net98.9 102.8 
Goodwill14,094.9 14,094.5 
Other intangible assets, net6,454.1 6,588.5 
Deferred taxes101.4 101.1 
Other assets400.9 405.9 
Total assets$25,635.8 $23,713.9 
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable$167.8 $150.8 
Accrued compensation208.2 309.8 
Deferred revenue1,120.3 1,130.2 
Other accrued liabilities413.0 440.7 
Income taxes payable793.0 132.0 
Current portion of long-term debt, net799.5 799.2 
Current liabilities held for sale 159.1 
Total current liabilities3,501.8 3,121.8 
Long-term debt, net of current portion6,654.8 7,122.6 
Deferred taxes1,476.1 1,479.5 
Other liabilities451.2 426.2 
Total liabilities12,083.9 12,150.1 
Commitments and contingencies (Note 10)
Common stock1.1 1.1 
Additional paid-in capital2,363.9 2,307.8 
Retained earnings11,410.4 9,455.6 
Accumulated other comprehensive loss(206.0)(183.1)
Treasury stock(17.5)(17.6)
Total stockholders' equity13,551.9 11,563.8 
Total liabilities and stockholders' equity$25,635.8 $23,713.9 
 
See accompanying notes to Condensed Consolidated Financial Statements.
5


Roper Technologies, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)
(in millions)
Three months ended March 31,
20222021
Cash flows from operating activities:
Net earnings from continuing operations$287.6 $269.9 
Adjustments to reconcile net earnings from continuing operations to cash flows from operating activities:
Depreciation and amortization of property, plant and equipment11.0 13.1 
Amortization of intangible assets148.1 146.3 
Amortization of deferred financing costs3.1 3.4 
Non-cash stock compensation35.9 31.6 
Gain on sale of assets, net of tax (21.6)
Income tax provision, excluding tax associated with gain on sale of assets79.065.7
Changes in operating assets and liabilities, net of acquired businesses:
Accounts receivable82.0 54.3 
Unbilled receivables(15.4)(17.8)
Inventories(27.7)(2.1)
Accounts payable17.9 13.3 
Other accrued liabilities (125.1)(59.0)
Deferred revenue29.4 60.9 
Cash income taxes paid(27.4)(17.2)
Other, net(24.6)(14.9)
Cash provided by operating activities from continuing operations473.8 525.9 
Cash provided by operating activities from discontinued operations1.5 33.7 
Cash provided by operating activities475.3 559.6 
Cash flows from (used in) investing activities:
Acquisitions of businesses, net of cash acquired(53.2) 
Capital expenditures(7.1)(7.1)
Capitalized software expenditures(7.5)(7.2)
Proceeds from sale of assets 27.1 
Other, net (0.1)
Cash (used in) provided by investing activities from continuing operations(67.8)12.7 
Proceeds from disposition of discontinued operations3,006.2  
Cash used in investing activities from discontinued operations(0.2)(2.0)
Cash provided by investing activities2,938.2 10.7 
Cash flows from (used in) financing activities:
Borrowings (payments) under revolving line of credit, net(470.0)(495.0)
Cash dividends to stockholders(65.3)(58.8)
Proceeds from stock-based compensation, net21.0 4.4 
Treasury stock sales5.5 4.7 
Other (0.1)
Cash flows used in financing activities from continuing operations(508.8)(544.8)
Cash flows used in financing activities from discontinued operations(11.4)(0.4)
Cash flows used in financing activities(520.2)(545.2)
(Continued)
6


Roper Technologies, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited) - Continued
(in millions)

Three months ended March 31,
20222021
Effect of foreign currency exchange rate changes on cash(7.3)(2.4)
Net increase in cash and cash equivalents2,886.0 22.7 
Cash and cash equivalents, beginning of period351.5 308.3 
Cash and cash equivalents, end of period$3,237.5 $331.0 


 
See accompanying notes to Condensed Consolidated Financial Statements.
7


Roper Technologies, Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)
(in millions)
Common
stock
Additional
paid-in
capital
Retained
earnings
Accumulated
other
comprehensive
loss
Treasury
stock
Total stockholders’ equity
Balances at December 31, 2021$1.1 $2,307.8 $9,455.6 $(183.1)$(17.6)$11,563.8 
Net earnings— — 2,020.5 — — 2,020.5 
Stock option exercises— 38.7 — — — 38.7 
Cash settlement of share-based awards in connection with disposition of discontinued operations— (11.1)— — — (11.1)
Treasury stock sold— 5.4 — — 0.1 5.5 
Currency translation adjustments— — — (22.9)— (22.9)
Stock-based compensation— 40.8 — — — 40.8 
Restricted stock activity— (17.7)— — — (17.7)
Dividends declared ($0.62 per share)
— — (65.7)— — (65.7)
Balances at March 31, 2022$1.1 $2,363.9 $11,410.4 $(206.0)$(17.5)$13,551.9 
Balances at December 31, 2020$1.1 $2,097.5 $8,546.2 $(147.0)$(18.0)$10,479.8 
Net earnings— — 289.0 — — 289.0 
Stock option exercises— 19.2 — — — 19.2 
Treasury stock sold— 4.6 — — 0.1 4.7 
Currency translation adjustments— — — 14.6 — 14.6 
Stock-based compensation— 32.4 — — — 32.4 
Restricted stock activity— (14.8)— — — (14.8)
Dividends declared ($0.5625 per share)
— — (59.2)— — (59.2)
Balances at March 31, 2021$1.1 $2,138.9 $8,776.0 $(132.4)$(17.9)$10,765.7 

See accompanying notes to Condensed Consolidated Financial Statements.
8




Roper Technologies, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
All currency and share amounts are in millions, except per share data

1.    Basis of Presentation

The accompanying Condensed Consolidated Financial Statements for the three months ended March 31, 2022 and 2021 are unaudited. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position, results of operations, comprehensive income and cash flows of Roper Technologies, Inc. and its subsidiaries (“Roper,” the “Company,” “we,” “our” or “us”) for all periods presented. The December 31, 2021 financial position data included herein was derived from the audited consolidated financial statements included in the Company’s 2021 Annual Report on Form 10-K (“Annual Report”) filed on February 22, 2022 with the Securities and Exchange Commission (“SEC”) but does not include all disclosures required by U.S. generally accepted accounting principles (“GAAP”).

Roper’s management has made estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities to prepare these Condensed Consolidated Financial Statements in conformity with GAAP. Actual results could differ from those estimates.

During 2021, the Company signed definitive agreements to divest our TransCore, Zetec and CIVCO Radiotherapy businesses. As of March 31, 2022, Roper has completed all three divestitures. The financial results for these businesses are presented as discontinued operations for all periods presented. Unless otherwise noted, discussion within these notes to the Condensed Consolidated Financial Statements relate to continuing operations. Refer to Note 5 for additional information on discontinued operations.

The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the full year. You should read these unaudited Condensed Consolidated Financial Statements in conjunction with Roper’s audited consolidated financial statements and the notes thereto included in its Annual Report. Certain prior period amounts have been reclassified to conform to current period presentation.

2.    Recent Accounting Pronouncements

The Financial Accounting Standards Board (“FASB”) establishes changes to accounting principles under GAAP in the form of accounting standards updates (“ASUs”) to the Accounting Standards Codification (“ASC”). The Company considers the applicability and impact of all ASUs. Any recent ASUs not listed were assessed and determined to be either not applicable or are expected to have an immaterial impact on the Company’s results of operations, financial position or cash flows.

3.    Weighted Average Shares Outstanding

Basic earnings per share were calculated using net earnings and the weighted average number of shares of common stock outstanding during the respective period. Diluted earnings per share were calculated using net earnings and the weighted average number of shares of common stock and potential common stock outstanding during the respective period. Potentially dilutive common stock consisted of stock options based upon the trading price of Roper’s common stock. The effects of potential common stock were determined using the treasury stock method. Weighted average shares outstanding are shown below:
9



Three months ended March 31,
20222021
Basic shares outstanding105.6 105.0 
Effect of potential common stock:
Common stock awards1.1 1.0 
Diluted shares outstanding106.7 106.0 

For the three months ended March 31, 2022, there were 0.840 outstanding stock options, respectively, that were not included in the determination of diluted earnings per share because doing so would have been antidilutive, as compared to 0.647 outstanding stock options that would have been antidilutive in the respective 2021 period.

4.    Business Acquisitions and Disposition

On January 3, 2022, Roper acquired the outstanding membership interests of Horizon Lab Systems, LLC, a provider of laboratory information management systems in the toxicology, environmental, public health and agricultural markets for an aggregate purchase price of $49.8. This acquisition has been integrated into our Clinisys business and its results are reported in the Application Software reportable segment. The results of operations of the acquired business are included in Roper’s Condensed Consolidated Financial Statements since the date of acquisition. Pro forma results of operations and the revenue and net income subsequent to the acquisition date has not been presented because the effects of the acquisition were not material to our financial results.

The Company recorded $25.6 in goodwill and $23.3 of other identifiable intangibles in connection with this acquisition. The amortizable intangible assets include customer relationships of $20.9 (15.1 year weighted average useful life) and technology of $2.4 (5.3 year weighted average useful life).

Disposition

On March 17, 2021, Roper completed the sale of a minority investment in Sedaru, Inc. for $27.1. The pretax gain on the sale was $27.1, which is reported in “Other income (expense), net” in the Condensed Consolidated Statement of Earnings.

5.    Discontinued Operations

During 2021, the Company signed definitive agreements to divest our TransCore, Zetec and CIVCO Radiotherapy businesses as described below.

On March 17, 2022, Roper closed on the divestiture of our TransCore business to an affiliate of Singapore Technologies Engineering Ltd., for approximately $2,680.0 in cash. The sale resulted in a pretax gain of $2,073.7 and income tax expense of $550.5, which are reported within “Gain on disposition of discontinued operations, net of tax” in the Condensed Consolidated Statements of Earnings. TransCore was previously included in the Network Software & Systems reportable segment.

On January 5, 2022, Roper closed on the divestiture of our Zetec business to Eddyfi NDT Inc. for approximately $350.0 in cash. The sale resulted in a pretax gain of $255.3 and income tax expense of $60.9, which are reported within “Gain on disposition of discontinued operations, net of tax” in the Condensed Consolidated Statements of Earnings. Zetec was previously included in the Process Technologies reportable segment.

On November 1, 2021, Roper closed the divestiture of our CIVCO Radiotherapy business to an affiliate of Blue Wolf Capital Partners LLC. CIVCO Radiotherapy business was previously included in the Measurement & Analytical Solutions reportable segment.

The Company concluded these disposal activities, in the aggregate, represented a strategic shift that will have a major effect on the Company’s operations and financial results. These divestitures significantly enhance our mix of high-margin, recurring revenue businesses and notably reduce our working capital requirements. Accordingly, the financial results of the TransCore, Zetec and CIVCO Radiotherapy businesses are presented in the Condensed Consolidated Financial Statements as discontinued operations for all periods presented. Current and non-current assets and liabilities of these businesses are presented in the
10


Condensed Consolidated Balance Sheet as assets and liabilities of discontinued operations classified as held for sale at December 31, 2021.

The following tables summarize the major classes of assets and liabilities related to the discontinued operations of the TransCore, Zetec and CIVCO Radiotherapy businesses, as reported in the Condensed Consolidated Balance Sheets at December 31, 2021:

Accounts receivable, net$74.7 
Inventories, net47.8 
Unbilled receivables158.2 
Goodwill405.5 
Other intangible assets, net31.0 
Other current assets71.4 
Current assets held for sale$788.6 
Accounts payable$40.3 
Accrued compensation27.0 
Deferred taxes29.5 
Other current liabilities62.3 
Current liabilities held for sale$159.1 

The following table summarizes the major classes of revenue and expenses constituting net income from discontinued operations attributable to the TransCore, Zetec and CIVCO Radiotherapy businesses:

Three Months Ended March 31,
20222021
Net revenues$100.4 $152.5 
Cost of sales71.2 94.7 
Gross profit29.2 57.8 
Selling, general and administrative expenses (1)
19.9 31.9 
Income from operations9.3 25.9 
Other income (expense), net0.1 (0.1)
Earnings before income taxes (2)
9.4 25.8 
Income taxes(6.2)6.7 
Earnings from discontinued operations, net of tax15.6 19.1 
Gain on disposition of discontinued operations, net of tax1,717.3  
Net earnings from discontinued operations$1,732.9 $19.1 
(1) Includes stock-based compensation expense of $0.9 and $1.3 for the three months ended March 31, 2022 and 2021, respectively. In connection with the sale of TransCore and Zetec, we recognized expense of $4.5 associated with accelerated vesting of share-based awards. The charges associated with accelerated vesting were recorded as a component of “Gain on disposition of discontinued operations, net of tax” within the Condensed Consolidated Statements of Earnings.
(2) During the three months ended March 31, 2022, there was no depreciation of property, plant and equipment or amortization of intangible assets given the asset classification as held for sale during the period. During the three months ended March 31, 2021 depreciation and amortization was $1.9.
11


6.    Stock Based Compensation

The Roper Technologies, Inc. 2021 Incentive Plan (“2021 Plan”) is a stock-based compensation plan used to grant incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights or equivalent instruments to Roper’s employees, officers, directors and consultants.

The following table provides information regarding the Company’s stock-based compensation expense:

Three Months Ended March 31,
20222021
Stock-based compensation$35.9 $31.6 
Tax effect recognized in net earnings from continuing operations7.5 6.6 

Stock Options - In the three months ended March 31, 2022, 0.365 options were granted with a weighted average fair value of $115.83 per option. During the same period in 2021, 0.498 options were granted with a weighted average fair value of $94.69 per option. All options were issued with an exercise price equal to the closing price of Roper’s common stock on the date of grant, as required by the 2021 Plan.

Roper records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. Historical data is used to estimate the expected price volatility, the expected dividend yield, the expected option life and the expected forfeiture rate. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the estimated life of the option.

The following weighted average assumptions were used to estimate the fair value of options granted during current and prior year periods using the Black-Scholes option-pricing model:

Three months ended March 31,
20222021
Risk-free interest rate (%)2.05 0.94 
Expected option life (years)5.635.61
Expected volatility (%)24.52 25.16 
Expected dividend yield (%)0.54 0.56 

Cash received from option exercises for the three months ended March 31, 2022 and 2021 was $38.7 and $19.2, respectively.

Restricted Stock Grants - During the three months ended March 31, 2022, the Company granted 0.219 shares with a weighted average grant date fair value of $455.84 per restricted share. During the same period in 2021, the Company granted 0.207 shares with a weighted average grant date fair value of $404.14 per restricted share. All grants were issued at grant date fair value.

During the three months ended March 31, 2022, 0.116 restricted shares vested with a weighted average grant date fair value of $329.75 per restricted share and a weighted average vest date fair value of $457.31 per restricted share.

Employee Stock Purchase Plan - Roper’s employee stock purchase plan (“ESPP”) allows employees in the U.S. and Canada to designate up to 10% of eligible earnings to purchase Roper’s common stock at a 10% discount on the lower of the closing price of the stock on the first and last day of each quarterly offering period. Common stock sold to employees pursuant to the ESPP may be either treasury stock, stock purchased on the open market, or newly issued shares.

During the three months ended March 31, 2022 and 2021, participants in the ESPP purchased 0.013 and 0.013 shares of Roper’s common stock for total consideration of $5.5 and $4.7, respectively. All shares were purchased from Roper’s treasury shares.

12


7.    Inventories

The components of inventory were as follows:

March 31,
2022
December 31,
2021
Raw materials and supplies$131.5 $112.7 
Work in process36.0 30.2 
Finished products72.1 69.3 
Inventory reserves(36.9)(36.1)
Inventories, net$202.7 $176.1 

8.    Goodwill and Other Intangible Assets

The carrying value of goodwill by segment was as follows:
Application SoftwareNetwork Software & SystemsMeasurement & Analytical SolutionsProcess TechnologiesTotal
Balances at December 31, 2021$8,889.3 $3,797.0 $1,160.6 $247.6 $14,094.5 
Additions25.6    25.6 
Other (0.5)  (0.5)
Currency translation adjustments(6.6)(12.1)(5.0)(1.0)(24.7)
Balances at March 31, 2022$8,908.3 $3,784.4 $1,155.6 $246.6 $14,094.9 

Other relates primarily to purchase accounting adjustments for acquisitions.

Other intangible assets were comprised of:

CostAccumulated
amortization
Net book
value
Assets subject to amortization:
Customer related intangibles$7,532.0 $(2,108.0)$5,424.0 
Unpatented technology906.4 (431.8)474.6 
Software149.5 (122.4)27.1 
Patents and other protective rights9.6 (2.1)7.5 
Trade names12.8 (6.1)6.7 
Assets not subject to amortization:
Trade names648.6 — 648.6 
Balances at December 31, 2021$9,258.9 $(2,670.4)$6,588.5 
Assets subject to amortization:
Customer related intangibles$7,527.0 $(2,205.3)$5,321.7 
Unpatented technology893.6 (445.6)448.0 
Software149.4 (125.2)24.2 
Patents and other protective rights9.6 (2.1)7.5 
Trade names16.3 (7.0)9.3 
Assets not subject to amortization:
Trade names643.4 — 643.4 
Balances at March 31, 2022$9,239.3 $(2,785.2)$6,454.1 

Amortization expense of other intangible assets was $145.8 and $145.1 during the three months ended March 31, 2022 and 2021, respectively.
13



An evaluation of the carrying value of goodwill and indefinite-lived intangibles is required to be performed on an annual basis and on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. There have been no events or changes in circumstances which indicate an interim impairment review is required in 2022. The Company will perform the annual analysis during the fourth quarter of 2022.

9.    Fair Value of Financial Instruments and Debt

Roper’s debt at March 31, 2022 included $7,500 of fixed-rate senior notes with the following fair values:

$500 3.125% senior notes due 2022
503 
$300 0.450% senior notes due 2022
299 
$700 3.650% senior notes due 2023
710 
$500 2.350% senior notes due 2024
493 
$300 3.850% senior notes due 2025
305 
$700 1.000% senior notes due 2025
650 
$700 3.800% senior notes due 2026
717 
$700 1.400% senior notes due 2027
635 
$800 4.200% senior notes due 2028
831 
$700 2.950% senior notes due 2029
675 
$600 2.000% senior notes due 2030
534 
$1,000 1.750% senior notes due 2031
864 

The fair values of the senior notes are based on the trading prices of each series of notes, which the Company has determined to be Level 2 in the FASB fair value hierarchy.

10.    Contingencies

Roper, in the ordinary course of business, is party to various pending or threatened legal actions, including product liability, intellectual property, data privacy and employment practices that, in general, are of a nature consistent with those over the past several years. After analyzing the Company’s contingent liabilities on a gross basis and, based upon past experience with resolution of such legal claims and the availability and limits of the primary, excess, and umbrella liability insurance coverages with respect to pending claims, management believes that adequate provision has been made to cover any potential liability not covered by insurance, and that the ultimate liability, if any, arising from these actions should not have a material adverse effect on Roper’s consolidated financial position, results of operations or cash flows. However, no assurances can be given in this regard.

Roper’s subsidiary, Vertafore, Inc., was named in three putative class actions, two in the U.S. District Court for the Southern District of Texas (Allen, et al. v. Vertafore, Inc., Case 4:20-cv-4139, filed December 4, 2020) and Masciotra, et al. v. Vertafore, Inc., (originally filed on December 8, 2020 as Case 1:20-cv-03603 in the U.S. District Court for the District of Colorado and subsequently transferred), and one in the U.S. District Court for the Northern District of Texas (Mulvey, et al. v. Vertafore, Inc., Case 3:21-cv-00213-E, filed January 31, 2021). In July 2021, the court granted Vertafore’s motion to dismiss the Allen Case. In March 2022, the U.S. Fifth Circuit Court of Appeals affirmed the lower court’s dismissal of the Allen case. In July 2021, the plaintiff in the Masciotra case voluntarily dismissed his action without prejudice. The Allen case and the Mulvey case each purport to represent approximately 27.7 million individuals who held Texas driver’s licenses prior to February 2019. In November 2020, Vertafore announced that as a result of human error, three data files were inadvertently stored in an unsecured external storage service that appears to have been accessed without authorization. The files, which included driver information for licenses issued before February 2019, contained Texas driver license numbers, as well as names, dates of birth, addresses and vehicle registration histories. The files did not contain any Social Security numbers or financial account information. These cases seek recovery under the Driver’s Privacy Protection Act, 18 U.S.C. § 2721. In addition, Roper was advised that the Texas Attorney General is investigating the data event.

Roper’s subsidiary, Verathon, Inc. (“Verathon”), is defending a patent infringement action pending in the United States District Court for the Western District of Washington (Berall v. Verathon, Inc., Case No. 2:2021mc00043). Plaintiff claims that video laryngoscopes and certain accessories sold by Verathon from approximately 2006 through 2016 infringe U.S. Patent 5,827,178 (the “‘178 Patent”). The complaint seeks an unspecified amount of damages, enhanced damages, attorneys’ fees, costs, and pre-
14


and post-judgment interest. Verathon contends that the products at issue do not infringe the ‘178 Patent and that the ‘178 Patent is invalid. Verathon is vigorously defending the matter.

Roper or our subsidiaries have been named defendants along with numerous industrial companies in asbestos-related litigation claims in certain U.S. states. To date, no significant resources have been required by Roper to respond to asbestos claims. In the first quarter of 2022, Roper completed a transaction in which it transferred the remainder of our exposure for asbestos claims to a third party. In connection with this transaction, Roper incurred a one-time charge of $4.1, which is recorded as a component of “Other income (expense), net” within the Condensed Consolidated Statements of Earnings.

11.    Business Segments

The following table presents selected financial information by reportable segment:

Three months ended March 31,
20222021Change %
Net revenues:
Application Software$631.5 $576.6 9.5 %
Network Software & Systems368.7 314.2 17.3 %
Measurement & Analytical Solutions392.4 369.6 6.2 %
Process Technologies134.0 115.7 15.8 %
Total$1,526.6 $1,376.1 10.9 %
Gross profit:
Application Software$437.8 $398.7 9.8 %
Network Software & Systems302.4 256.4 17.9 %
Measurement & Analytical Solutions217.6 218.2 (0.3)%
Process Technologies72.3 62.7 15.3 %
Total$1,030.1 $936.0 10.1 %
Operating profit*:
Application Software$173.8 $153.7 13.1 %
Network Software & Systems145.4 114.1 27.4 %
Measurement & Analytical Solutions115.9 121.5 (4.6)%
Process Technologies41.8 35.1 19.1 %
Total$476.9 $424.4 12.4 %
Long-lived assets:
Application Software$135.8 $126.7 7.2 %
Network Software & Systems28.5 27.8 2.5 %
Measurement & Analytical Solutions32.5 33.9 (4.1)%
Process Technologies13.3 18.3 (27.3)%
Total$210.1 $206.7 1.6 %
 
*Segment operating profit is before unallocated corporate general and administrative expenses. These expenses were $55.8 and $49.8 for the three months ended March 31, 2022 and 2021, respectively.

15


12.    Revenues from Contracts

Disaggregated Revenue - We disaggregate our revenues into two categories: (i) software and related services; and (ii) engineered products and related services. Software and related services revenues are primarily derived from our Application Software and Network Software & Systems reportable segments. Engineered products and related services revenues are derived from all of our reportable segments except Application Software and comprise substantially all of the revenues generated in our Measurement & Analytical Solutions and Process Technologies reportable segments. See details in the table below.

Three Months Ended March 31,
20222021
Software and related services$970.0 $864.5 
Engineered products and related services556.6 511.6 
Net revenues$1,526.6 $1,376.1 

Remaining performance obligations - Remaining performance obligations represent the transaction price of firm orders for which work has not been performed and excludes unexercised contract options. As of March 31, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $4,000.3. We expect to recognize revenue of $2,718.0, or approximately 68% of our remaining performance obligations over the next 12 months (“Backlog”), with the remainder to be recognized thereafter.

Contract balances
Balance Sheet AccountMarch 31, 2022December 31, 2021Change
Unbilled receivables $110.0 $95.3 $14.7 
Deferred revenue - current(1,120.3)(1,130.2)9.9 
Deferred revenue - non-current (1)
(111.5)(75.3)(36.2)
Net contract assets/(liabilities)$(1,121.8)$(1,110.2)$(11.6)
(1) The non-current portion of deferred revenue is included in “Other liabilities” in our Condensed Consolidated Balance Sheets.

The change in our net contract assets/(liabilities) from December 31, 2021 to March 31, 2022 was due primarily to the timing of payments and invoicing relating to Software-as-a-Service (“SaaS”) and post contract support (“PCS”) renewals, partially offset by the increase in unbilled receivables due to the timing of invoicing primarily related to software milestone billings associated with multi-year term license renewals and software implementations.

Most of the Company’s project-based contracts where the input method of revenue recognition is utilized are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in unbilled receivables where billing occurs after revenue recognition. The Company records deferred revenue when cash payments are received or due in advance of the Company’s performance relating primarily to SaaS and PCS renewals. Revenue recognized from the deferred revenue balance on December 31, 2021 and 2020 was $495.7 and $450.9 for the three months ended March 31, 2022 and 2021, respectively.

In order to determine revenues recognized in the period, we allocate revenue to the individual deferred revenue balance outstanding at the beginning of the year until the revenue exceeds that balance.

The current and non-current portions of deferred commissions are included in “Other current assets” and “Other assets,” respectively, in our Condensed Consolidated Balance Sheets. At March 31, 2022 and December 31, 2021, we had $58.3 and $56.7 of deferred commissions, respectively.

16


ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on form 10-K for the year ended December 31, 2021 (“Annual Report”) as filed on February 22, 2022 with the U.S. Securities and Exchange Commission (“SEC”) and the Notes to Condensed Consolidated Financial Statements included elsewhere in this report.

Information About Forward-Looking Statements

This report includes “forward-looking statements” within the meaning of the federal securities laws. In addition, we, or our executive officers on our behalf, may from time to time make forward-looking statements in reports and other documents we file with the SEC or in connection with oral statements made to the press, potential investors or others. All statements that are not historical facts are “forward-looking statements.” Forward-looking statements may be indicated by words or phrases such as “anticipate,” “estimate,” “plans,” “expects,” “projects,” “should,” “will,” “believes” or “intends” and similar words and phrases. These statements reflect management’s current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such risks and uncertainties include any ongoing impacts of the COVID-19 pandemic on our business, operations, financial results and liquidity, which will depend on numerous evolving factors that we cannot accurately predict or assess, including: the duration and scope of the pandemic, new variants of the virus and the distribution and efficacy of vaccines; the impact of vaccine mandates on our workforce in certain jurisdictions; any negative impact on global and regional markets, economies and economic activity; actions governments, businesses and individuals take in response to the pandemic; the effects of the pandemic, including all of the foregoing, on our employees, customers, suppliers, and business partners, and how quickly economies and demand for our products and services recover following the pandemic.

Examples of forward-looking statements in this report include but are not limited to statements regarding operating results, the success of our operating plans, our expectations regarding our ability to generate cash and reduce debt and associated interest expense, profit and cash flow expectations, the prospects for newly acquired businesses to be integrated and contribute to future growth and our expectations regarding growth through acquisitions. Important assumptions relating to the forward-looking statements include, among others, demand for our products, the cost, timing and success of product upgrades and new product introductions, raw material costs, expected pricing levels, expected outcomes of pending litigation, competitive conditions and general economic conditions. These assumptions could prove inaccurate. Although we believe that the estimates and projections reflected in the forward-looking statements are reasonable, our expectations may prove to be incorrect. Important factors that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to:

general economic conditions;
difficulty making acquisitions and successfully integrating acquired businesses;
any unforeseen liabilities associated with future acquisitions;
limitations on our business imposed by our indebtedness;
unfavorable changes in foreign exchange rates;
failure to effectively mitigate cybersecurity threats, including any litigation arising therefrom;
failure to comply with new data privacy laws and regulations, including any litigation arising therefrom;
difficulties associated with exports/imports and risks of changes to tariff rates;
risks and costs associated with our international sales and operations;
rising interest rates;
product liability and insurance risks;
increased warranty exposure;
future competition;
the cyclical nature of some of our markets;
reduction of business with large customers;
risks associated with government contracts;
changes in the supply of, or price for, labor, energy, raw materials, parts and components, including as a result of impacts from the current inflationary environment, ongoing supply chain constraints or outbreaks of COVID-19;
environmental compliance costs and liabilities;
potential write-offs of our goodwill and other intangible assets;
our ability to successfully develop new products;
failure to protect our intellectual property;
the effect of, or change in, government regulations (including tax);
17


economic disruption caused by armed conflicts (such as the war in Ukraine), terrorist attacks, health crises (such as the COVID-19 pandemic) or other unforeseen geopolitical events; and
the factors discussed in other reports we file with the SEC from time to time.

You should not place undue reliance on any forward-looking statements, which are based on current expectations. Further, forward-looking statements speak only as of the date they are made, and we undertake no obligation to publicly update any of these statements in light of new information or future events.

Overview

Roper is a diversified technology company. We operate market leading businesses that design and develop vertical software and application-specific products for a variety of defensible niche markets.

We pursue consistent and sustainable growth in revenue, earnings and cash flow by emphasizing continuous improvement in the operating performance of our businesses. In addition, we utilize a disciplined, analytical and process-driven approach to redeploy our excess free cash flow toward high-quality acquisitions.

Discontinued Operations

During 2021, the Company signed definitive agreements to divest our TransCore, Zetec and CIVCO Radiotherapy businesses. As of March 31, 2022, Roper has completed all three divestitures. The financial results of these businesses are classified as discontinued operations and certain prior period amounts have been reclassified to conform to current period presentation. Information regarding discontinued operations is included in Note 5 of the Notes to Condensed Consolidated Financial Statements.

Critical Accounting Policies

There were no material changes during the three months ended March 31, 2022 to the items that we disclosed as our critical accounting policies and estimates in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report.

Recently Issued Accounting Standards

Information regarding new accounting pronouncements is included in Note 2 of the Notes to Condensed Consolidated Financial Statements.

Impact of COVID-19 on our Business

The extent to which the COVID-19 pandemic impacts our business, results of operations and financial condition will depend on future developments, which are highly uncertain and are difficult to predict, including, but not limited to, the duration and spread of the outbreak and its severity, the actions to contain the virus and its variants including the distribution, administration and efficacy of available vaccines, the impact of vaccine mandates on our workforce, and how quickly and to what extent normal economic and operating conditions can resume. As a result of the effects of the COVID-19 global pandemic our ability to obtain products or services from certain suppliers and to operate at certain locations have been and may continue to be impacted. If COVID-19 and its variants continue to spread, particularly in countries with low vaccination rates, certain countries may experience more severe and lasting impacts from the pandemic. To the extent we have operations and/or customers in these countries, we may experience adverse impacts on our businesses located in such countries.

18


Results of Continuing Operations
All currency amounts are in millions, percentages are of net revenues

Percentages may not sum due to rounding.

The following table sets forth selected information for the periods indicated.
Three months ended March 31,
20222021
Net revenues:
Application Software$631.5 $576.6 
Network Software & Systems368.7 314.2 
Measurement & Analytical Solutions392.4 369.6 
Process Technologies134.0 115.7 
Total$1,526.6 $1,376.1 
Gross margin:
Application Software69.3 %69.1 %
Network Software & Systems82.0 81.6 
Measurement & Analytical Solutions55.5 59.0 
Process Technologies54.0 54.2 
Total67.5 68.0 
Selling, general and administrative expenses:
Application Software41.8 %42.5 %
Network Software & Systems42.6 45.3 
Measurement & Analytical Solutions25.9 26.2 
Process Technologies22.8 23.9 
Total36.2 37.2 
Segment operating margin:
Application Software27.5 %26.7 %
Network Software & Systems39.4 36.3 
Measurement & Analytical Solutions29.5 32.9 
Process Technologies31.2 30.3 
Total31.2 30.8 
Corporate administrative expenses(3.7)(3.6)
Income from operations27.6 27.2 
Interest expense, net(3.4)(4.4)
Other income (expense), net(0.1)2.0 
Earnings before income taxes24.0 24.8 
Income taxes(5.2)(5.2)
Net earnings from continuing operations18.8 %19.6 %

19


Three months ended March 31, 2022 compared to three months ended March 31, 2021

Net revenues for the three months ended March 31, 2022 increased by 10.9% as compared to the three months ended March 31, 2021. The components of revenue growth for the three months ended March 31, 2022 were as follows:

Application SoftwareNetwork Software & SystemsMeasurement & Analytical SolutionsProcess TechnologiesRoper
Total Revenue Growth9.5 %17.3 %6.2 %15.9 %10.9 %
Less Impact of:
Acquisitions/Divestitures1.0 1.5 — — 0.8 
Foreign Exchange(0.6)(0.3)(1.1)(1.7)(0.8)
Organic Revenue Growth9.1 %16.1 %7.3 %17.6 %10.9 %

In our Application Software segment, revenues were $631.5 in the three months ended March 31, 2022 as compared to $576.6 in the three months ended March 31, 2021. The growth of 9.1% in organic revenues was broad-based across the segment led by our businesses serving property and casualty insurance, government contracting, and acute healthcare markets. Gross margin increased to 69.3% in the three months ended March 31, 2022 as compared to 69.1% in the three months ended March 31, 2021 due primarily to operating leverage on higher organic revenues and revenue mix. SG&A expenses decreased as a percentage of revenue to 41.8% in the three months ended March 31, 2022 as compared to 42.5% in the three months ended March 31, 2021 due to operating leverage on higher organic revenues. The resulting operating margin was 27.5% in the three months ended March 31, 2022 as compared to 26.7% in the three months ended March 31, 2021.

In our Network Software & Systems segment, revenues were $368.7 in the three months ended March 31, 2022 as compared to $314.2 in the three months ended March 31, 2021. The growth of 16.1% in organic revenues was broad-based across the segment led by our network software businesses serving the freight match, media and entertainment and life insurance markets. Gross margin increased to 82.0% in the three months ended March 31, 2022 as compared to 81.6% in the three months ended March 31, 2021 due primarily to revenue mix. SG&A expenses decreased as a percentage of revenues at 42.6% in the three months ended March 31, 2022 as compared to 45.3% in the three months ended March 31, 2021 due primarily to operating leverage on higher organic sales combined with revenue mix. As a result, operating margin was 39.4% in the three months ended March 31, 2022 as compared to 36.3% in the three months ended March 31, 2021.

In our Measurement & Analytical Solutions segment, revenues were $392.4 in the three months ended March 31, 2022 as compared to $369.6 in the three months ended March 31, 2021. The growth of 7.3% in organic revenues was primarily due to our water meter technology business and industrial businesses. Gross margin decreased to 55.5% in the three months ended March 31, 2022 as compared to 59.0% in the three months ended March 31, 2021 due primarily to higher material, component and freight costs as our businesses navigate the widespread global supply chain challenges. SG&A expenses as a percentage of revenues decreased to 25.9% in the three months ended March 31, 2022 as compared to 26.2% in the three months ended March 31, 2021 due primarily to revenue mix. The resulting operating margin was 29.5% in the three months ended March 31, 2022 as compared to 32.9% in the three months ended March 31, 2021.

In our Process Technologies segment, revenues were $134.0 in the three months ended March 31, 2022 as compared to $115.7 in the three months ended March 31, 2021. The growth of 17.6% in organic revenues was broad-based across the segment led by a recovery in oil and gas markets. Gross margin decreased to 54.0% in the three months ended March 31, 2022 as compared to 54.2% in the three months ended March 31, 2021 due to primarily to revenue mix partially offset by higher operating leverage on organic revenues. SG&A expenses as a percentage of revenues decreased to 22.8% in the three months ended March 31, 2022 as compared to 23.9% in the three months ended March 31, 2021 due to operating leverage on higher organic revenues. As a result, operating margin was 31.2% in the three months ended March 31, 2022 as compared to 30.3% in the three months ended March 31, 2021.

Corporate expenses increased to $55.8, or 3.7% of revenues, in the three months ended March 31, 2022 as compared to $49.8, or 3.6% of revenues, in the three months ended March 31, 2021. The dollar increase was due primarily to higher compensation and professional services expense.

Net interest expense decreased to $52.6 for the three months ended March 31, 2022 as compared to $60.6 for the three months ended March 31, 2021 due to lower weighted average debt balances associated with our credit facility and fixed debt.

20


Other expense, net, of $1.9 for the three months ended March 31, 2022 was composed primarily of a one-time charge associated with a transaction to transfer the remainder of our exposure related to asbestos claims to a third party, partially offset by foreign exchange gains at our non-U.S. based subsidiaries. Other income, net, of $27.1 for the three months ended March 31, 2021 was composed primarily of a gain on sale of minority investment of $27.1.

Income taxes as a percent of pretax earnings were 21.5% for the three months ended March 31, 2022 as compared to 20.9% for the three months ended March 31, 2021. The rate was impacted by the timing of a tax benefit associated with an internal restructuring plan that occurred in the first quarter of 2021.

Backlog is equal to our remaining performance obligations expected to be recognized within the next 12 months as discussed in Note 12 of the Notes to Condensed Consolidated Financial Statements. Backlog increased 28% to $2,718.0 at March 31, 2022 as compared to $2,131.6 at March 31, 2021. Organic growth in backlog was 27% and acquisitions contributed 1%.

Backlog as of
March 31,
20222021
Application Software$1,567.5 $1,394.6 
Network Software & Systems476.5 382.1 
Measurement & Analytical Solutions508.8 248.5 
Process Technologies165.2 106.4 
Total$2,718.0 $2,131.6 

Financial Condition, Liquidity and Capital Resources
All currency amounts are in millions

Selected cash flows for the three months ended March 31, 2022 and 2021 were as follows:

Three months ended March 31,
Cash provided by/(used in):20222021
Continuing operations:
Cash provided by operating activities$473.8 $525.9 
Cash (used in) provided by investing activities$(67.8)$12.7 
Cash used in financing activities$(508.8)$(544.8)
Cash flows provided by discontinued operations$2,996.1 $31.3 

Operating activities - Net cash provided by operating activities from continuing operations decreased by 10% to $473.8 in the three months ended March 31, 2022 as compared to $525.9 in the three months ended March 31, 2021, due primarily to less cash provided by working capital associated with higher incentive compensation payments in the first quarter of 2022 associated with 2021 performance and approximately $36 of accelerated cash receipts in the first quarter of 2021 generated from our UK-based laboratory software business. These decreases were partially offset by higher net income from continuing operations net of non-cash expenses.

Investing activities - Cash used in investing activities from continuing operations during the three months ended March 31, 2022 is due to a business acquisition and capital expenditures. Cash provided by investing activities from continuing operations during the three months ended March 31, 2021 was due primarily to the proceeds from the sale of a minority investment, partially offset by capital expenditures.

Financing activities - Cash used in financing activities from continuing operations for the three months ended March 31, 2022 was primarily due to repayments on our unsecured credit facility and dividend payments, partially offset by net proceeds from stock based compensation. Cash used in financing activities from continuing operations during the three months ended March 31, 2021 was primarily due to net repayments on our unsecured credit facility and dividend payments.

Discontinued operations - Cash provided by discontinued operations for the three months ended March 31, 2022 was primarily due to proceeds from the sale of TransCore and Zetec slightly offset by less cash provided by discontinued operations which was impacted by the timing of our divestiture activity. Cash provided by discontinued operations during the three months ended
21


March 31, 2021 was primarily due to net income net of non-cash expenses and cash provided by working capital primarily associated with the timing of payments related to accounts receivable.

Effect of foreign currency exchange rate changes on cash - Cash and cash equivalents decreased during the three months ended March 31, 2022 by $7.3 due primarily to the strengthening of the U.S. dollar against the functional currencies of our European and United Kingdom subsidiaries partially offset by weakening of the U.S. dollar against our Canadian subsidiaries. Cash and cash equivalents decreased during the three months ended March 31, 2021 by $2.4 due primarily to the strengthening of the U.S. dollar against the functional currencies of our European subsidiaries.

Total debt at March 31, 2022 consisted of the following:

$500 3.125% senior notes due 2022$500.0 
$300 0.450% senior notes due 2022300.0 
$700 3.650% senior notes due 2023700.0 
$500 2.350% senior notes due 2024500.0 
$300 3.850% senior notes due 2025300.0 
$700 1.000% senior notes due 2025700.0 
$700 3.800% senior notes due 2026700.0 
$700 1.400% senior notes due 2027700.0 
$800 4.200% senior notes due 2028800.0 
$700 2.950% senior notes due 2029700.0 
$600 2.000% senior notes due 2030600.0 
$1,000 1.750% senior notes due 20311,000.0 
Unsecured credit facility— 
Deferred finance costs(45.9)
Other0.2 
Total debt, net of deferred finance costs7,454.3 
Less current portion799.5 
Long-term debt, net of deferred finance costs$6,654.8 

The interest rate on borrowings under our $3,000.0 unsecured credit facility is calculated based upon various recognized indices plus a margin as defined in the credit facility. At March 31, 2022, we had no outstanding borrowings under our unsecured credit facility and $20.3 of outstanding letters of credit.

Cash at our foreign subsidiaries at March 31, 2022 increased to $394 as compared to $311 at December 31, 2021 due primarily to the cash generated at our foreign subsidiaries during the three months ended March 31, 2022, partially offset by the repatriation of $29 during the three months ended March 31, 2022. We intend to repatriate substantially all historical and future earnings.

We expect existing cash balances, together with cash generated by our operations and amounts available under our credit facility, will be sufficient to fund our operating requirements for the foreseeable future.

We were in compliance with all debt covenants related to our unsecured credit facility throughout the three months ended March 31, 2022.

22


Net working capital (total current assets, excluding cash and current assets held for sale, less total current liabilities, excluding debt and current liabilities held for sale) decreased to negative $1,454.2 at March 31, 2022 as compared to negative $882.5 at December 31, 2021 primarily driven by an increase in income taxes payable associated with the divestitures of TransCore and Zetec and a reduction in accounts receivable, partially offset by a decrease in accrued compensation. Consistent negative net working capital demonstrates Roper’s continued evolution and focus on asset-light business models. Total debt was $7,454.3 at March 31, 2022 as compared to $7,921.8 at December 31, 2021, due primarily to the net repayments under our unsecured credit facility. Our leverage on a continuing operations basis is shown in the following table:

March 31,
2022
December 31,
2021
Total debt$7,454.3 $7,921.8 
Cash(3,237.5)(351.5)
Net debt4,216.8 7,570.3 
Stockholders’ equity13,551.9 11,563.8 
Total net capital$17,768.7 $19,134.1 
Net debt / total net capital23.7 %39.6 %

Capital expenditures were $7.1 for the three months ended March 31, 2022 as compared to $7.1 for the three months ended March 31, 2021. Capitalized software expenditures were $7.5 for the three months ended March 31, 2022 as compared to $7.2 for the three months ended March 31, 2021. We expect the aggregate of capital expenditures and capitalized software expenditures for the balance of the year to be comparable to prior years as a percentage of revenues.

Off-Balance Sheet Arrangements

At March 31, 2022, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Outlook

Current geopolitical and economic uncertainties could adversely affect our business prospects. The COVID-19 pandemic has had, and may continue to have, an adverse impact on our business. An armed conflict (such as the war in Ukraine), significant terrorist attack, other global conflict, or public health crisis could cause changes in world economies that would adversely affect us. It is impossible to isolate each of these potential factor’s future effects on current economic conditions or any of our businesses. It is also impossible to predict with any reasonable degree of certainty what or when any additional events may occur that also would similarly disrupt the economy and have an adverse impact on our businesses.

We maintain an active acquisition program; however, future acquisitions will be dependent on numerous factors and it is not feasible to reasonably estimate if or when any such acquisitions will occur and what the impact will be on our business, financial condition and results of operations. Such acquisitions may be financed by the use of existing credit lines, future cash flows from operations, announced divestitures, future divestitures, the proceeds from the issuance of new debt or equity securities or any combination of these methods, the terms and availability of which will be subject to market and economic conditions generally.

We anticipate that our businesses will generate positive cash flows from operating activities, and that these cash flows will permit the reduction of currently outstanding debt in accordance with the repayment schedule. However, the rate at which we can reduce our debt (and reduce the associated interest expense) will be affected by, among other things, the financing and operating requirements of any new acquisitions, the financial performance of our existing companies and the impact of the COVID-19 pandemic on our business prospects and the financial markets generally. None of these factors can be predicted with certainty.

23


ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

See “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in our Annual Report. There were no material changes during the three months ended March 31, 2022.

ITEM 4.    CONTROLS AND PROCEDURES

As required by SEC rules, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q (“Evaluation Date”). This evaluation was carried out under the supervision and with the participation of our management, including our principal executive officer and principal financial officer. Based on this evaluation as of the Evaluation Date, these officers have concluded that the design and operation of our disclosure controls and procedures are effective.

Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes to our internal controls during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

24



PART II.    OTHER INFORMATION
 
ITEM 1.    LEGAL PROCEEDINGS

Information pertaining to legal proceedings can be found in Note 10 of the Notes to Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference herein.

ITEM 1A.    RISK FACTORS

Information regarding risk factors can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Information About Forward-Looking Statements,” in Part 1 - Item 2 of this Form 10-Q and in Part 1 - Item 1A of our 2021 Annual Report on Form 10-K. We are providing the following information regarding changes that have occurred to the previously disclosed risk factors in our Form 10-K. Except for such additional information, there were no material changes during the three months ended March 31, 2022 to the risk factors reported in the 2021 Annual Report on Form 10-K.

Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by the ongoing conflict between Russia and Ukraine.

The global economy has been negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the United States, United Kingdom and European Union have each imposed export controls on certain products and financial and economic sanctions on certain industry sectors and parties in Russia. We have historically had limited operations in Russia and a limited number of suppliers in Ukraine. Nevertheless, the Russia-Ukraine military conflict could have a negative impact on the global supply chain logistics or economy. Further escalation of geopolitical tensions related to the military conflict, including increased trade barriers or restrictions on global trade, could result in, amon